887243-08-5Relevant academic research and scientific papers
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
Thomson, Stephen A.,Banker, Pierette,Bickett, D. Mark,Boucheron, Joyce A.,Carter, H. Luke,Clancy, Daphne C.,Cooper, Joel P.,Dickerson, Scott H.,Garrido, Dulce M.,Nolte, Robert T.,Peat, Andrew J.,Sheckler, Lauren R.,Sparks, Steven M.,Tavares, Francis X.,Wang, Liping,Wang, Tony Y.,Weiel, James E.
scheme or table, p. 1177 - 1182 (2009/09/04)
Key binding interactions of the anthranilimide based glycogen phosphorylase a (GPa) inhibitor 2 from X-ray crystallography studies are described. This series of compounds bind to the AMP site of GP. Using the binding information the core and the phenyl ur
GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 111, (2010/11/30)
The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia,
